Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Vinod Labhasetwar
Cleveland Clinic Lerner Com Cwru, Department: Other Basic Sciences
Should you be removed from our database? Contact us at [email protected]. Read more below.
ProTransit Nanotherapy, LLC
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
This study involves the comparison of the Pro-NP technology licensed to ProTransit to placebo. For this reason, the Innovation Management and Conflict of Interest Committee at Cleveland Clinic determined that Dr. Labhasetwar’s Significant Financial Interest is related to the research and could directly and significantly affect the design, conduct, or reporting of the research constituting a Public Health Service-Reportable Financial Conflict of Interest.
Stroke Therapy
Project Narrative Stroke is a leading cause of death, long-term disability, and socioeconomic costs, highlighting the urgent need for more effective treatments. Intravenous administration of tissue plasminogen activator (t-PA) is the only FDA-approved therapy to re-establish cerebral blood flow but it cannot be used in most stroke patients because of increased risk of hemorrhage beyond 3 h post stroke, its neurotoxic effects, can also aggravate the extent of reperfusion injury. In the proposed study, we will develop efficient antioxidant delivery system (nano- SOD/catalase) to protect brain from reperfusion injury. An effective treatment could benefit more stroke patients than can be treated with t-PA alone because of the extended window of treatment and reduced risk of hemorrhagic complications. Further, nano-SOD/catalase could prevent neuroinflammation and facilitate neuronal repair mechanisms that could significantly improve the post-stroke recovery.
Filed on May 13, 2015.
Tell us what you know about Vinod Labhasetwar's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Vinod Labhasetwar filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Vinod Labhasetwar | Cleveland Clinic Lerner Com Cwru | Conflict of Interest | ProTransit Nanotherapy, LLC | Value cannot be readily determined |
| Vinod Labhasetwar | Cleveland Clinic Lerner Com Cwru | Conflict of Interest | ProTransit Nanotherapy, LLC | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.